Overview

Combination Therapy With GEN0101 and Pembrolizmub in Advanced Melanoma Patients PIb/PII

Status:
Recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
This is a multi-center, open-labeled, non-randomized, single arm investigator-initiated trial to evaluate the safety and efficacy of GEN0101 and Pembrolizmub combination in patients with advanced melanoma.
Phase:
Phase 2
Details
Lead Sponsor:
Osaka University
Collaborators:
ISHIHARA SANGYO KAISHA,LTD
ISHIHARA SANGYO KAISHA,LTD. Japan
Merck Sharp & Dohme Corp.